A personalized cancer vaccine developed using mRNA technology has shown a 100 percent response rate in a phase 2 clinical trial, eliminating tumors in all 30 participants with advanced melanoma. The vaccine is custom-designed for each patient based on their tumor's genetic profile.
"These results are unprecedented in cancer treatment," said lead investigator Dr. Jeffrey Weber of NYU Langone Health. "A 100 percent response rate in advanced melanoma is remarkable, and the durability of responses suggests this approach could fundamentally change how we treat cancer."
The vaccine works by training the immune system to recognize and attack cancer cells carrying specific genetic mutations unique to each patient's tumor. The manufacturing process analyzes the tumor's genetic material to identify optimal targets.
Participants received the personalized vaccine alongside Merck's Keytruda, an immunotherapy drug. The combination approach achieved complete remission in all 30 patients after a median follow-up of 18 months, with no recurrences observed.
"This represents the realization of personalized medicine's promise for cancer treatment," said Dr. James Guo of the Dana-Farber Cancer Institute. "Every cancer is genetically unique, and now we have a way to exploit those differences."